Cargando…
Intelligent tunable CAR-T cell therapy leads the new trend
Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still rais...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518343/ https://www.ncbi.nlm.nih.gov/pubmed/37753197 http://dx.doi.org/10.1016/j.synbio.2023.09.001 |
_version_ | 1785109492858355712 |
---|---|
author | Cheng, Jiayi Liu, Mingyao Zhang, Jiqin |
author_facet | Cheng, Jiayi Liu, Mingyao Zhang, Jiqin |
author_sort | Cheng, Jiayi |
collection | PubMed |
description | Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years. |
format | Online Article Text |
id | pubmed-10518343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-105183432023-09-26 Intelligent tunable CAR-T cell therapy leads the new trend Cheng, Jiayi Liu, Mingyao Zhang, Jiqin Synth Syst Biotechnol Review Article Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years. KeAi Publishing 2023-09-14 /pmc/articles/PMC10518343/ /pubmed/37753197 http://dx.doi.org/10.1016/j.synbio.2023.09.001 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Cheng, Jiayi Liu, Mingyao Zhang, Jiqin Intelligent tunable CAR-T cell therapy leads the new trend |
title | Intelligent tunable CAR-T cell therapy leads the new trend |
title_full | Intelligent tunable CAR-T cell therapy leads the new trend |
title_fullStr | Intelligent tunable CAR-T cell therapy leads the new trend |
title_full_unstemmed | Intelligent tunable CAR-T cell therapy leads the new trend |
title_short | Intelligent tunable CAR-T cell therapy leads the new trend |
title_sort | intelligent tunable car-t cell therapy leads the new trend |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518343/ https://www.ncbi.nlm.nih.gov/pubmed/37753197 http://dx.doi.org/10.1016/j.synbio.2023.09.001 |
work_keys_str_mv | AT chengjiayi intelligenttunablecartcelltherapyleadsthenewtrend AT liumingyao intelligenttunablecartcelltherapyleadsthenewtrend AT zhangjiqin intelligenttunablecartcelltherapyleadsthenewtrend |